A Practical Framework for Biopharma Sponsors Navigating Final Product Analytics
Bispecific antibodies have moved from a niche engineering exercise to a mainstream therapeutic format, but their final product release testing still don’t have a settled playbook. Unlike conventional monoclonal antibodies, where decades of precedent have converged on a fairly standard release panel, bispecifics introduce a structural wrinkle: two distinct binding arms that must both assemble correctly and both function, which many legacy methods were never built to catch. For sponsors moving a bispecific toward the clinic or beyond, understanding where standard analytics hold up, where they fall short, and how to build a release strategy that survives the transition from Phase 1 to BLA is one of the more consequential technical decisions in the program.
Start from the Target Product Profile, Not the Assay Catalog
The starting point for any release strategy begins with the Target Product Profile (TPP), which defines the intended clinical use, and overall product goals. As product knowledge evolves through characterization, development, and nonclinical studies, sponsors gain a clearer understanding of the quality attributes, impurities, and product variants that could affect safety, efficacy, or consistency. The analytical strategy and release testing program are then built to monitor those attributes and confirm that every manufactured batch remains fit for its intended use. While the exact release panel depends on the molecule, modality, stage of development, and risk profile, most programs ultimately focus on three broad areas: safety, product quality, and biological activity.
The first is safety-driven microbiology, including endotoxin, bioburden, and, where applicable, sterility. The second is a physicochemical, purity and identity panel designed to confirm that the molecule reaching the patient is the same molecule that was characterized during development. This typically includes protein concentration, purity by CE-SDS, aggregation by SEC, charge variant profile by icIEF, pH, and osmolality, and identity testing that often progresses from chromatographic or charge-based approaches early in development to mass spectrometry-based confirmation in later stages. The third category is potency, typically measured through an ELISA or a cell-based activity assay selected to reflect the molecule’s mechanism of action. Across bispecific products, the panel also has to account for process-related impurities such as host cell proteins, residual host-cell DNA, and residual purification reagents or affinity ligands such as Protein A. For bispecific Antibody-drug conjugates (ADCs), the panel extends further to include conjugate-specific attributes such as drug-to-antibody ratio (DAR), drug-load distribution, unconjugated antibody, free payload, and linker-payload-related impurities.
Why Each Method Earns Its Place
Every method in that panel is answering a specific question. Microbiology safety tests catch contamination that would make a product clinically unusable regardless of its pharmacology. Physicochemical methods confirm that the molecule reaching the patient matches the one characterized in nonclinical studies: reduced and non-reduced CE-SDS purity confirms the intact molecule and its subunits integrity; SEC aggregation data guards against species with altered pharmacokinetics or immunogenic potential and charge variant profiling flags post-translational modifications that can affect binding or Fc function.
For bispecific formats, specifically potency assay design, deserves particular scrutiny. A single-antigen binding ELISA confirms that one arm is functional but says nothing about the other, a molecule with a compromised second arm can pass undetected. A more informative approach is a dual-binding ELISA, in which one target antigen serves as capture and the second mediates detection, so the signal depends on the molecule engaging both antigens simultaneously rather than relying on two independent ELISA methods. When designed well, this format enriches signal for correctly assembled molecules and reduces the risk of releasing product with a compromised arm. For bispecific ADCs, DAR testing and free-payload analysis extend the panel further, helping confirm that conjugate chemistry hasn’t degraded in ways that alter the therapeutic index.
Where Regulatory Guidance Stands and Where it Doesn’t
Bispecific antibodies are regulated within the general biologics framework, but their structural complexity often creates analytical questions that existing guidance addresses only indirectly. ICH Q6B provides the foundation for establishing specifications for biological products, including identity, purity, impurities, potency, and quantity, while emphasizing that specifications are only one component of a broader control strategy that also includes product characterization, process controls, manufacturing consistency, and stability assessment.
ICH Q2(R2) covers analytical validation, and ICH Q14 introduces a risk-based approach to analytical procedure development and lifecycle management. FDA has also published guidance addressing quality and CMC considerations for bispecific antibody development. Together, these documents provide a strong framework for product development and analytical control, but none prescribe a standard release-testing panel for bispecific antibodies. As a result, sponsors must build and justify a release strategy that reflects the specific characteristics of their molecule. The methods selected for release testing should be scientifically justified based on product structure, mechanism of action, manufacturing process, stability profile, and the quality attributes considered important for ensuring safety, efficacy, and consistency. Regulators have generally accepted phase-appropriate, fit-for-purpose approaches during early clinical development, provided the underlying scientific rationale is clear and the control strategy evolves as product understanding increases. For bispecific ADCs, expectations extend beyond traditional biologic release testing and often incorporate additional assessment of conjugate-related attributes such as drug loading, free payload, and payload-related impurities.
The Limits of Conventional Methods
Standard CE-SDS and SEC methods were largely optimized in monoclonal antibody contexts, and they detect size-based variants well. But they can struggle with asymmetric bispecific formats built from multiple subunits, where incorrect heavy-chain or light-chain pairing generates species similar enough in size, charge, or electrophoretic behavior to slip past conventional release assays. Chain mispairing is a distinct analytical problem, and one these methods weren’t originally designed to resolve.
Potency assays carry a different set of challenges. A dual-binding ELISA addresses arm functionality efficiently, but the most rigorous confirmation of bispecific activity requires a cell-based assay that engages both targets simultaneously. These assays are substantially more demanding to develop and validate than their monoclonal antibody counterparts; cell model selection, receptor density, and assay dynamic range all require careful optimization, and the path from a research-grade assay to a GMP-validated release method can take years. Biological variability in cell-based systems also makes reproducibility across sites and operators harder to demonstrate. Process impurity methods, meanwhile, face throughput and sensitivity constraints that become acute in a release setting, where turnaround time is finite and sample volume is limited.
Emerging Approaches to Chain Mispairing
Chain mispairing is arguably the defining analytical challenge of bispecific release, and the field is pursuing two main paths forward. The first is optimization of existing chromatographic methods. Reverse-phase HPLC, with careful method development, can achieve resolution between correctly assembled bispecific molecules and mispaired species. Charge variant assays such as IEX and cIEF/icIEF can contribute where mispairing produces a detectably distinct charge profile, though this depends on the isoelectric point (pI) difference between the mismatched chains and is therefore format specific. Enzymatic digestion steps that generate discrete Fc and Fab fragments prior to separation can improve resolution further by reducing the molecular complexity the chromatographic assay has to discriminate. These approaches are compatible with release environments and can, in principle, be validated for lot release.
The second path is mass spectrometry. Intact and subunit-level MS provides high-confidence, mass-based structural confirmation and can detect mispairing with high sensitivity. In development and extended characterization settings, MS is increasingly routine; its translation into release is constrained by throughput, cost, and cGMP validation requirements, but for complex bispecific formats, the case for including MS in extended characterization panels, even where it hasn’t yet earned a place in routine release, is a strong one. MS can also support the development of charge-based methods by supporting the identification of the charge variant in hyphenated or off-line methods.
Best Practices: Build the Analytical Groundwork Before You Build the Assays
The most consistent predictor of a successful release program is the quality of the analytical groundwork established early in development. The process begins with the Target Product Profile (TPP), which defines the intended clinical use and overall product goals. As product knowledge grows through characterization, process development, and nonclinical and clinical studies, sponsors identify the quality attributes that are most important to product safety, efficacy, and consistency. Analytical Target Profiles (ATPs) can then be used to define the performance requirements for the analytical procedures needed to measure and control those attributes. Establishing this framework early enables teams to develop methods against predefined objectives rather than qualifying methods around the capabilities or limitations of an existing process. For bispecifics, that means identifying attributes such as correct subunit assembly and pairing fidelity before selecting the analytical approaches used to monitor them.
A phase-appropriate philosophy matters just as much. Early clinical programs rarely need the same level of analytical control expected for commercial release, but the methods selected in Phase 1 should be chosen with future development in mind. Rather than being replaced as a program matures, analytical methods should ideally evolve through optimization, qualification, and validation as product understanding increases. Selecting platforms with a credible path to regulatory validation from the outset can reduce analytical redevelopment, preserve historical knowledge, and help avoid delays later in development as programs approach BLA or MAA submission
Two Things Sponsors Underestimate
Two points are worth particular attention. First, the distinction between release testing and extended characterization is more important than it is often given credit for. Release testing confirms that a batch meets predefined specifications and is suitable for disposition, while extended characterization provides the deeper understanding of the molecule needed to support development, comparability, process changes, and regulatory submissions. For bispecific antibodies, where subunit assembly, chain pairing, and structural complexity present unique analytical challenges, extended characterization generates much of the evidence used to demonstrate product understanding and justify the overall control strategy. A release panel may confirm batch conformance, but the broader characterization package is often what establishes confidence that the selected tests are truly fit for purpose.
Second, potency assay design for bispecifics requires early strategic investment. A cell-based assay capable of simultaneously engaging both targets and detecting the loss of either binding arm offers the most biologically relevant assessment of activity, but it can be challenging to develop, optimize, and validate. Developing that assay early, qualifying it progressively, and building the performance history needed to support validation is often a multi-year undertaking. Programs that postpone this work risk advancing into late-stage development with potency methods that are difficult to validate, transfer, or defend during regulatory review.
In conclusion, bispecific antibody release testing sits at the intersection of molecular complexity and evolving industry practice. While existing regulatory guidance provides a strong framework for analytical control and specification setting, there is no universally accepted release-testing template for bispecifics. The programs that navigate this most successfully are typically those that invest early in product understanding, build a phase-appropriate analytical strategy, and view analytical development as a strategic component of CMC development rather than a downstream deliverable.
